Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026
Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026
Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Fineline Cube May 19, 2026
Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Fineline Cube May 19, 2026
Company Deals

Silence Therapeutics Receives $4 Million Milestone Payment from Hansoh Pharmaceutical

Fineline Cube Jul 14, 2023

UK-based Silence Therapeutics plc (NASDAQ: SLN) has announced the receipt of a $4 million milestone...

Company

Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results

Fineline Cube Jul 14, 2023

Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...

Company Deals

InnoCare Pharma and ArriVent Biopharma Partner on SHP2 Inhibitor and EGFR Inhibitor Combination

Fineline Cube Jul 14, 2023

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced a clinical development collaboration with US-based...

Company Drug

GSK’s Cabotegravir Receives NMPA Approval for HIV Treatment in China

Fineline Cube Jul 14, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for GlaxoSmithKline’s (GSK, NYSE: GSK)...

Company Medical Device

Beijing Tinavi Medical’s Knee Replacement Navigation System Approved by NMPA

Fineline Cube Jul 14, 2023

Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has received marketing approval from the National...

Company Deals

GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs

Fineline Cube Jul 14, 2023

China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South...

Company Drug

BeiGene’s Brukinsa Receives US FDA Review for Relapsed/Refractory Follicular Lymphoma sNDA

Fineline Cube Jul 13, 2023

China-based biotechnology company BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer

Fineline Cube Jul 13, 2023

Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed...

Company Policy / Regulatory

US FDA Approves Additional Shipments of Qilu Pharmaceutical’s Cisplatin to Address Shortage

Fineline Cube Jul 13, 2023

The US Food and Drug Administration (FDA) is maintaining its reliance on China-based Qilu Pharmaceutical...

Company Drug

Shanghai Fosun Pharmaceutical Submits Tenapanor Approval Application to China’s NMPA

Fineline Cube Jul 13, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...

Company Deals

DNE Group Launches $485 Million Fund for Life Sciences Park in Shanghai Pudong

Fineline Cube Jul 13, 2023

China-based infrastructure investor DNE Group has revealed that it has raised a new fund worth...

Company Deals

LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial

Fineline Cube Jul 13, 2023

Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement...

Company Deals

Medidata Partners with ECCO and GoBroad to Transform Cancer Trials with Digital Tech

Fineline Cube Jul 13, 2023

Medidata, a wholly owned subsidiary of France firm Dassault Systèmes (EPA: DSY), has announced a...

Company Deals

Shanghai Circode Bio and Pfizer Collaborate to Explore Circular RNA Therapy Potential

Fineline Cube Jul 13, 2023

Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)...

Company Drug

Kedrion Biopharma Achieves First Product Approval in China for Human Albumin

Fineline Cube Jul 13, 2023

Italy-headquartered blood products specialist Kedrion Biopharma has announced that its subsidiary, Bio Products Laboratory (BPL),...

Company Drug

GRIT Biotechnology’s GT201 TIL Therapy Approved for Clinical Studies by China’s CDE

Fineline Cube Jul 13, 2023

The Center for Drug Evaluation (CDE) website has indicated that GRIT Biotechnology, a China-based cell...

Company Deals

Novartis Terminates TIGIT-Targeted Antibody Deal with BeiGene, Retains Rights to Ociperlimab

Fineline Cube Jul 12, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has decided to terminate an option and license...

Company Legal / IP

Biocytogen Pharmaceuticals Awarded CNIPA Patent for RenMab Human Antibody Mice Platform

Fineline Cube Jul 12, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced receiving a...

Company Deals Medical Device

Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations

Fineline Cube Jul 12, 2023

OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Irinotecan and Bupivacaine Liposome Injections Get Clinical Trial Green Light in China

Fineline Cube Jul 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate...

Posts pagination

1 … 505 506 507 … 668

Recent updates

  • Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment
  • Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline
  • Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval
  • Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town
  • Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.